公开(公告)号：WO2016187308A1

公开(公告)日：2016-11-24

申请号：PCT/US2016/033088

申请日：2016-05-18

Applicant: AMGEN INC.

Inventor： CHEN, Ning ,  CHEN, Xiaoqi ,  CHEN, Yinhong ,  CHENG, Alan C. ,  CONNORS, Richard V. ,  DEIGNAN, Jeffrey ,  DRANSFIELD, Paul John ,  DU, Xiaohui ,  FU, Zice ,  HEATH, Julie Anne ,  HORNE, Daniel B. ,  HOUZE, Jonathan ,  KALLER, Matthew R. ,  KHAKOO, Aarif Yusuf ,  KOPECKY, David John ,  LAI, Su-Jen ,  MA, Zhihua ,  MCGEE, Lawrence R. ,  MEDINA, Julio C. ,  MIHALIC, Jeffrey T. ,  NISHIMURA, Nobuko ,  OLSON, Steven H. ,  PATTAROPONG, Vatee ,  SWAMINATH, Gayathri ,  WANG, Xiaodong ,  YANG, Kevin ,  YEH, Wen-Chen ,  DEBENEDETTO, Mikkel V. ,  FARRELL, Robert P. ,  HEDLEY, Simon J. ,  JUDD, Ted C. ,  KAYSER, Frank

IPC: C07D401/14 ,  C07D401/04 ,  C07D413/04 ,  A61K31/4196 ,  A61K31/4439 ,  A61P9/00

CPC classification number: C07D401/14 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/513 ,  A61K31/695 ,  A61K45/06 ,  C07B57/00 ,  C07B59/002 ,  C07B2200/05 ,  C07B2200/07 ,  C07C311/13 ,  C07D211/54 ,  C07D213/61 ,  C07D213/71 ,  C07D213/82 ,  C07D239/26 ,  C07D239/30 ,  C07D239/34 ,  C07D241/12 ,  C07D241/18 ,  C07D241/24 ,  C07D249/08 ,  C07D295/16 ,  C07D401/04 ,  C07D401/12 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07F7/08

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures where the definitions of the variables are provided herein.

Abstract translation: 式I和式II的化合物，其药学上可接受的盐，前述任何一种的立体异构体或其混合物是APJ受体的激动剂，并且可用于治疗心血管和其它病症。 式I和式II的化合物具有以下结构，其中本文提供变量的定义。

公开(公告)号：WO2021225835A1

公开(公告)日：2021-11-11

申请号：PCT/US2021/029526

申请日：2021-04-28

Applicant: AMGEN INC.

Inventor： FARRELL, Robert P. ,  TEDROW, Jason S.

IPC: C07D267/16

Abstract: Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound (E), wherein R1 is described herein. Compound (E) can be useful in synthesizing compound (A1), or a salt or solvate thereof, and compound (A2), or a salt of solvate thereof.